HBV相关慢加急性肝衰竭患者血清IL-32和IL-10水平变化及意义

顾静; 王艳; 陈丽; 徐英; 甘建和

doi:10.3969/j.issn.1001-5256.2018.04.021

HBV相关慢加急性肝衰竭患者血清IL-32和IL-10水平变化及意义

DOI: 10.3969/j.issn.1001-5256.2018.04.021

苏州大学附属第一医院感染病科

基金项目:

国家科技部“十二五”重大专项(2012X10002004-008)；

详细信息

中图分类号: R512.62;R575.3
计量
- 文章访问数: 2635
- HTML全文浏览量: 84
- PDF下载量: 414
- 被引次数: 0
出版历程
- 出版日期: 2018-04-20

Changes in serum levels of interleukin-32 and interleukin-10 and their clinical significance in patients with HBV-related acute-on-chronic liver failure

Department of Infectious Diseases, The First Affiliated Hospital of Soochow University

Research funding:

摘要

摘要:
目的探讨HBV相关慢加急性肝衰竭（HBV-ACLF）患者血清IL-32和IL-10水平的变化规律及临床意义。方法选取2012年9月-2014年3月在苏州大学附属第一医院住院治疗的38例HBV-ACLF患者、20例慢性乙型肝炎（CHB）患者及20例健康对照者,采用ELISA法动态监测血清IL-32和IL-10水平变化,同时比较HBV-ACLF早中晚期、感染组与非感染组、存活组与死亡组IL-32、IL-10水平。计量资料2组间比较采用t检验,多组间比较采用方差分析,进一步2组间比较采用SNK-q检验。结果 HBV-ACLF组IL-32水平[（500.98±152.33）pg/ml]显著高于CHB组[（281.72±99.28）pg/ml]及健康对照组[（178.16±50.54）pg/ml]（P值均<0.05）;HBV-ACLF组IL-10水平[（4.82±1.03）pg/ml]显著高于CHB组[（3.15±0.98）pg/ml]及健康对照组[（1.62±0.43）pg/ml]（P值均<0.05）。动态监测HBV-ACLF组IL-32水平显示,HBV-ACLF早期高于中期[（5...
- 肝功能衰竭 /
- 肝炎病毒,乙型 /
- 白细胞介素10 /
- 白细胞介素32
Abstract:
Objective To investigate the changes in the serum levels of interleukin-32 (IL-32) and interleukin-10 (IL-10) and their clinical significance in patients with HBV-related acute-on-chronic liver failure (HBV-ACLF) .Methods A total of 38 HBV-ACLF patients who were hospitalized and treated in The First Affiliated Hospital of Soochow University from September 2012 to March 2014 were enrolled as HBV-ACLF group, as well as 20 patients with chronic hepatitis B (CHB) (CHB group) and 20 healthy controls (healthy control group) .ELISA was used for dynamic monitoring of the changes in the serum levels of IL-32 and IL-10.The serum levels of IL-32 and IL-10 were compared between early-, middle-, and late-stage HBV-ACLF groups, between infection group and non-infection group, and between survival group and death group.The t-test was used for comparison of continuous data between two groups; an analysis of variance was used for comparison between multiple groups, and the SNK-q test was used for further comparison between two groups.Results Compared with the CHB group and the healthy control group, the HBV-ACLF group had significantly higher levels of IL-32 (500.98 ± 152.33 pg/ml vs 281.72 ± 99.28 pg/ml and 178.16 ± 50.54 pg/ml, both P < 0.05) and IL-10 (4.82 ± 1.03 pg/ml vs3.15 ± 0.98 pg/ml and 1.62 ± 0.43 pg/ml, both P < 0.05) .Dynamic monitoring of IL-32 level in the HBV-ACLF group showed that the early-stage HBV-ACLF group had a significantly higher level than the middle-stage HBV-ACLF group (540.69 ± 155.71 pg/ml vs 498.43 ± 135.56 pg/ml, P < 0.05) , and the middle-stage HBV-ACLF group had a significantly higher level than the late-stage HBV-ACLF group (498.43 ± 135.56 pg/ml vs 450.77 ± 102.33 pg/ml, P < 0.05) ; as for the level of IL-10, the early-stage HBV-ACLF group had a significantly lower level than the middle-stage HBV-ACLF group (1.94 ± 0.44 pg/ml vs 2.83 ± 0.97 pg/ml, P < 0.05) , and the middle-stage HBV-ACLF group had a significantly lower level than the late-stage HBV-ACLF group (2.83 ± 0.97 pg/ml vs 3.69 ± 1.23 pg/ml, P < 0.05) .The HBV-ACLF infection group had a significantly higher level of IL-32 than the non-infection group (553.41 ± 158.65 pg/ml vs 482.54 ± 110.16 pg/ml, P = 0.021) .Compared with the HBV-ACLF death group, the HBV-ACLF survival group had a significantly lower level of IL-32 (481.95 ± 100.67 pg/ml vs 540.62 ± 112.45 pg/ml, P = 0.011) and a significantly higher level of IL-10 (4.21 ± 1.27 pg/ml vs 3.61 ± 1.05 pg/ml, P = 0.038) .Conclusion The cytokine network plays an important role in the pathogenesis of HBV-ACLF.Serum IL-32 and IL-10 may be involved in disease progression, and dynamic monitoring of their levels helps with prognostic prediction.
- liver failure /
- hepatitis B virus /
- interleukin-10 /
- interleukin-32

HTML全文

参考文献(23)

[1]SARIN SK, KUMAR A, ALMEIDA JA, et al.Acute-on-chronic liver failure:consensus recommodations of the Asian Pacific Association for the study of the liver (APASL) [J].Hepatol Int, 2009, 3 (1) :269-282.

[2]CHEN EQ, ZENG F, ZHOU LY, et al.Early warning and clinical outcome prediction of acute-on-chronic hepatitis B liver failure[J].World J Gastroenterol, 2015, 21 (42) :11964-11973.

[3]KRENKEL O, MOSSANEN JC, TACKE F.Immune mechanisms in acetaminophen-induced acute liver failure[J].Hepatobiliary Surg Nutr, 2014, 3 (6) :331-343.

[4]SHI JX, SU X, XU J, et al.MK2 posttranscriptionally regulates TNF-α-induced expression of ICAM-1 and IL-8 via tristeraprolin in human pulmonary microvascular endothelial cells[J].Am J Physiol Lung Cell Mol Physiol, 2012, 302 (8) :793-799.

[5]BERRY PA, ANTONIADES CG, HUSSAIN MJ, et al.Admission levels and early changes in serum interleukin-10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis[J].Liver lnt, 2010, 30 (5) :733-740.

[6] Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association;Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for diagnosis and treatment liver failure[J].Chin J Clin Infect Dis, 2012, 5 (6) :321-327. (in Chinese) 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南 (2012年版) [J].中华临床感染病杂志, 2012, 5 (6) :321-327.

[7]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention andtreatment for chronic hepatitis B:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1941-1960. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1941-1960.

[8]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[9]TANG YZ, CHEN Z, WANG L, et al.Relationship between immune state and prognosis of patients with HBV-related acute-on-chronic liver failure[J/CD].Chin J Liver Dis:Electronic Edition, 2016, 8 (3) :69-73. (in Chinese) 唐玉珍, 陈竹, 王丽, 等.乙型肝炎相关慢加急性肝衰竭患者的免疫状态及其与预后的相关性[J/CD].中国肝脏病杂志:电子版, 2016, 8 (3) :69-73.

[10]HEINHUIS B, KOENDERS MI, van RIEL PL, et al.Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade[J].Ann Rheum Dis, 2011, 70 (4) :660-667.

[11]KHAWAR B, ABBASI MH, SHEIKH N.A panoramic spectrum of complex interplay between the immune system and IL-32 during pathogenesis of various systemic infections and inflammation[J].Eur J Med Res, 2015, 20 (1) :7-12.

[12]XU WD, ZHANG M, FENG CC, et al.IL-32 with potential insights into rheumatoid arthritis[J].Clin Immunol, 2013, 147 (2) :89-94.

[13]MONTELEONE K, DI MAIO P, CACCIOTTI G, et al.Interleukin-32 isoforms:expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients[J].Med Microbiol Immunol, 2014, 203 (3) :207-216.

[14]PAN X, CAO H, LU J, et al.Interleukin-32 expression induced by hepatitis B virus protein X is mediated through activation of NF-κB[J].Mol Immunol, 2011, 48 (12-13) :1573-1577.

[15]WANG MH, ZOU MY, ZHANG YY, et al.The expression and significance of interleukin 32 in hepatitis B related liver failure[C]//Compilation of Papers of Chinese Medical Association Sixteenth National Academic Conference on Viral Hepatitis and Liver Disease, 2013:414-415. (in Chinese) 汪美华, 邹美银, 章幼奕, 等.白介素32在乙肝相关性肝衰竭中的表达及意义[C]//中华医学会第十六次全国病毒性肝炎及肝病学术会议论文汇编, 2013:414-415.

[16]ZHANG Y, XU CM, ZUO WZ, et al.Changes and clinical significance of peripheral blood T cell subsets, IL-32 and IL-6 in patients with hepatitis B[J].Chin J Gastroenterol, 2010, 15 (8) :471-474. (in Chinese) 张艳, 许春梅, 左维泽, 等.乙型肝炎患者外周血T细胞亚群、IL-32、IL-6水平的变化及临床意义[J].胃肠病学, 2010, 15 (8) :471-474.

[17]ZOU Y, BAO J, PAN X, et al.NKP30-B7-H6 interaction aggravates hepatocyte damage through up-regulation of interleukin-32 expression in hepatitis B virus-related acute-on-chronic liver failure[J].PLo S One, 2015, 10 (8) :e0134568.

[18]SHEN C, YAN WZ, ZHAO CY, et al.Increased CD4+CD25+regulatory T cells correlate with poor short-term outcomes in hepatitis B virus-related acute-on-chronic liver failure patients[J].J Microbiol Immunol Infect, 2015, 48 (2) :137-146.

[19]LIU GW, TANG KC, LI Q, et al.Changes of IL-1, TNF-Alpha, IL-12 and IL-10 levels with chronic liver failure[J].Surg Sci, 2011, 2 (2) :69-72.

[20]WANG CM, MENG ZJ, CHEN Y, et al.Value of serum PCT in early diagnosis of bacterial infection in patients with liver failure[J].J Clin Hepatol, 2017, 33 (6) :1137-1140. (in Chinese) 王传敏, 孟忠吉, 陈悦, 等.血清降钙素原检测对肝衰竭合并感染的早期诊断价值[J].临床肝胆病杂志, 2017, 33 (6) :1137-1140.

[21]KIM SJ, LEE S, KWAK A, et al.Interleukin-32γtransgenic mice resist LPS-mediated septic shock[J].J Microbiol Biotechnol, 2014, 24 (8) :1133-1142.

[22]CONTI P, YOUINOU P, THEOHARIDES TC.Modulation of automunity by the latest interleukins (with special emphasis on IL-32) [J].Autoimmune Rev, 2007, 6 (3) :131-137.

[23]XU Q, PAN X, SHU X, et al.Increased interleukin-32 expression in chronic hepatitis B virus-infected liver[J].J Infect, 2012, 65 (4) :336-342.

施引文献

资源附件(0)

访问统计